Your browser doesn't support javascript.
loading
Clinical Response of Nuberol Forte® for Pain Management With Musculoskeletal Conditions in Routine Pakistani Practice (NFORTE-EFFECT).
Noor, Syed Shahid; Najjad, Muhammad Kazim; Ahmed, Nasir; Anwar, Khurram; Memon, Abdul; Riaz, Tehseen; Hanif, Muhammad; Maqbool, Nauman; Ahmed, Saeed; Ahmed, Israr; Khanzada, Ali Yasir.
Afiliação
  • Noor SS; Orthopedics and Trauma, Liaquat National Hospital and Medical College, Karachi, PAK.
  • Najjad MK; Orthopedic Surgery, Liaquat National Hospital, Karachi, PAK.
  • Ahmed N; Orthopedics, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
  • Anwar K; Periodontology, Isra University Hospital, Hyderabad, PAK.
  • Memon A; Family Medicine, Family Clinic, Mirpurkhas, PAK.
  • Riaz T; Orthopedic Surgery, Jinnah Hospital, Lahore, PAK.
  • Hanif M; Orthopedic Surgery, Lahore General Hospital, Lahore, PAK.
  • Maqbool N; Orthopedic Surgery, Fauji Foundation, Rawalpindi, PAK.
  • Ahmed S; Orthopedics, Life Care International Hospital, Islamabad, PAK.
  • Ahmed I; Orthopedics and Spinal Surgery, Hayatabad Medical Complex, Peshawar, PAK.
  • Khanzada AY; Clinical Research, The Searle Company Limited, Karachi, PAK.
Cureus ; 14(3): e23011, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35415025
Background Musculoskeletal pain is the most common complaint presented to the health practitioner. It is well-known that untreated or under-treated pain can have a significant negative impact on an individual's quality of life (QoL). Objectives The current study aimed to assess the clinical response of Nuberol Forte® (paracetamol 650 mg + orphenadrine 50 mg) to musculoskeletal pain in routine Pakistani practice and its impact on improving the patient's QoL. Methods A prospective, observational multicenter study (NFORT-EFFECT: Safety & Efficacy of Nuberol Forte in Pain Management). Three hundred ninety-nine patients with known prescreened musculoskeletal pain were recruited from 10 major healthcare facilities across six (6) major cities of Pakistan, as per the inclusion/exclusion criteria. After the baseline visit (Visit 1), the patients were followed up one to two weeks (Visit 2) after the treatment as per the physician's discretion. Data were collected using the Case Report Form (CRF) designed for the study, and adverse events (AEs) were also monitored to assess drug safety. Pain intensity was assessed through a visual analog scale (VAS), and QoL was assessed using the Muscle and Joint Measure (MJM) scale. Results Out of 399 enrolled patients, 49.4% were males and 50.6% were females with a mean age of 47.24 ± 14.20 years. Most patients were presented with knee osteoarthritis (OA), i.e., 148 (38%), followed by backache 70 (18.2%). A significant reduction in the mean pain score was observed after treatment with the combination of paracetamol and orphenadrine (p<0.05). Furthermore, an overall improvement in the patient's QoL was also observed. During the study, only 10 patients reported mild adverse events (AEs), namely, dryness of the mouth, dizziness, gastric irritation, tachycardia, restlessness, etc. Conclusion The combination of paracetamol and orphenadrine (Nuberol Forte) exhibited effective pain management among patients with musculoskeletal conditions and improved their QoL.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2022 Tipo de documento: Article